https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-61-from-58-at-stifel

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia Gravis and chronic inflammatory demyelinating polyneuropathy studies. The firm believes both studies support its thesis that IMVT-1402 is a highly-derisked asset within the growing/strategically-important fragment crystallizable receptor space. Bottom line, Stifel added that it updated its Immunovant model to reflect IMVT-1402 as the lead in MG/CIDP, removing marginal risk-adjusted near team revenue for Batoclimab.

Light Up your Portfolio with Spark:

Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed  competitor analyses.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on IMVT:

Questions or Comments about the article? Write to [email protected]

Immunovant price target lowered to $33 from $38 at BofA Immunovant data positive for Biohaven, says Deutsche Bank Immunovant’s Promising Clinical Trial Results and Market Dynamics Drive Buy Rating Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

View Comments